Alps Group Inc Announces Potential Pipeline Expansion Beyond CELESOME(+) Following Publication of Nebulized Human Umbilical Cord Mesenchymal Stem Cell Exosome Therapy

Alps Group (NASDAQ:ALPS) announced potential expansion of its exosome pipeline beyond CELESOME(+) following publication of a peer‑reviewed retrospective clinical case series on nebulized hUCMSC‑derived exosomes in patients with asthma and/or COPD.

Rhea-AI Summary

Alps Group (NASDAQ:ALPS) announced potential expansion of its exosome pipeline beyond CELESOME(+) following publication of a peer‑reviewed retrospective clinical case series on nebulized hUCMSC‑derived exosomes in patients with asthma and/or COPD.

The published series reports observed improvements in pulmonary function, stable inflammatory markers, and no significant adverse effects after weekly 30‑minute nebulized dosing for five weeks (1 ml exosome solution mixed with 5 ml saline).

Positive

• Published clinical observations report pulmonary function improvements
• No significant adverse effects observed in the case series
• Defined dosing protocol: 1 ml exosome solution + 5 ml saline, 30 minutes weekly for 5 weeks

Negative

• Evidence limited to a retrospective, observational case series without randomized controls
• Findings are preliminary and require larger controlled studies to confirm
• No guarantee of regulatory approval or successful clinical development

Argus Jan 30 session

+4.29% close to close Open Argus

Details

News Market Reaction – ALPS

On Jan 30, the day this news came out, ALPS closed 4.29% above the previous close.

Data tracked by StockTitan Argus for the Jan 30 session.

Key Figures

Asthma prevalence: 260 million individuals COPD prevalence: 400 million individuals Exosome dose volume: 1 ml +5 more

Asthma prevalence

260 million individuals

Global burden cited from BMJ Open Respiratory Research 2025

COPD prevalence

400 million individuals

Global burden cited from Montes de Oca et al., 2025

Exosome dose volume

1 ml

Exosome solution per treatment dose

Saline volume

5 ml

Saline mixed with exosome solution per treatment dose

Nebulization duration

30 minutes

Inhalation time per treatment session

Dosing frequency

Once weekly

Frequency of nebulized administration

Treatment period

5 weeks

Total duration of the reported treatment regimen

NMRR ID

NMRR ID-25-00600-F4A

Study registration in National Medical Research Register, Malaysia

Historical Context

2 past events · Latest: Jan 08

2 events

1. Jan 08

   CFO appointment

   24h Move

   +2.0%

   New CFO appointed to lead finance, risk management, and treasury functions.

2. Oct 31

   Business combination

   24h Move

   +15800.6%

   Completion of business combination and Nasdaq listing with PIPE financing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nebulized, human umbilical cord mesenchymal stem cell, exosome, chronic obstructive pulmonary disease, +4 more

8 terms

nebulized medical

"describing nebulized human umbilical cord mesenchymal stem cell (“hUCMSC”) derived exosome"

Nebulized means a liquid medicine has been turned into a fine mist so it can be breathed directly into the airways and lungs using a small device. For investors, nebulized delivery matters because it can change how well a treatment works, who can use it, the types of devices and manufacturing needed, and the regulatory steps required — think of it like delivering medicine with a spray instead of a pill.

human umbilical cord mesenchymal stem cell medical

"describing nebulized human umbilical cord mesenchymal stem cell (“hUCMSC”) derived exosome"

A human umbilical cord mesenchymal stem cell is a type of versatile cell collected from the tissue of a newborn’s umbilical cord that can develop into several kinds of body tissue and influence the immune system. For investors, these cells matter because they are the ‘building blocks’ used in regenerative medicine and cell therapies, so progress in trials, manufacturing scale-up, or regulation can directly affect a company’s future revenue and risk profile.

exosome medical

"potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+)"

Small membrane-bound particles that cells naturally release to carry proteins, genetic material and signaling molecules to other cells; think of them as microscopic packages or text messages cells use to communicate. They matter to investors because exosomes are being explored both as sources of diagnostic information (biomarkers that can reveal disease earlier or more precisely) and as vehicles for targeted therapies or drug delivery, which could create new markets or change treatment costs.

chronic obstructive pulmonary disease medical

"in patient with asthma and/or chronic obstructive pulmonary disease (“COPD“)."

Chronic obstructive pulmonary disease (COPD) is a long-lasting lung condition that makes breathing progressively harder by narrowing airways and destroying air sacs, like an increasingly clogged and leaky air pipe. It matters to investors because COPD represents a large, growing market for treatments, diagnostics and medical devices, influences healthcare spending and insurance costs, and is a frequent focus of regulatory reviews and clinical trials that can materially affect company value.

biotechnology technical

"a fully integrated biotechnology research and healthcare platform specializing in"

Biotechnology is the use of living cells, molecules, or biological processes as tools to create products, treatments, or industrial processes—think of it as using nature’s toolbox to solve problems like disease, food production, or pollution. For investors it matters because biotech ventures can deliver big breakthroughs and rapid growth but also face long development timelines, strict regulatory checks, and binary outcomes (success or failure), so potential reward comes with significant risk and uncertainty.

nebulizer medical

"administered via inhalation using a medical-grade electronic nebulizer for 30 minutes"

A nebulizer is a medical device that turns liquid medication into a fine mist a patient breathes in through a mouthpiece or mask, delivering drugs directly to the lungs for conditions like asthma or chronic bronchitis. Investors care because nebulizers are physical products tied to manufacturing, recurring sales of consumables and medications, and subject to safety reviews and reimbursement rules — factors that influence revenue and risk much like the steady demand for a household appliance plus its replacement parts.

inflammatory markers medical

"suggest improvements in pulmonary function, stability in inflammatory markers,"

Inflammatory markers are measurable substances in blood or tissue—such as certain proteins—that rise or fall when the body has inflammation, like warning lights on a dashboard signaling an internal problem. Investors watch them because changes in these markers can indicate whether a drug or treatment is working, affect clinical trial outcomes, regulatory decisions, and ultimately influence the commercial prospects and valuation of healthcare companies.

retrospective case series medical

"This retrospective case series reports preliminary clinical observations relating to"

A retrospective case series is a study that reviews and summarizes a group of past patients who received the same treatment or had the same condition, using existing records rather than new experiments. It can reveal patterns or early signals about safety and outcomes—like looking through old photos to spot a trend—but does not include a comparison group and cannot prove cause and effect, so investors should treat its findings as preliminary when judging clinical or commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced a potential expansion of its exosome-related pipeline beyond its previously disclosed CELESOME(+) program. The announcement follows the publication of a preliminary retrospective clinical case series in SAGE Open Medical Case Reports describing nebulized human umbilical cord mesenchymal stem cell (“hUCMSC”) derived exosome in patient with asthma and/or chronic obstructive pulmonary disease (“COPD“). The clinical case series study was registered with the National Medical Research Register, Ministry of Health Malaysia (NMRR ID-25-00600-F4A).

The Company has previously disclosed development activities relating to exosome-infused candidates under the CELESOME(+) program. Building on technical experience developed in connection with exosome isolation, handling, and characterization activities described under CELESOME(+), the published report describes observational findings from an investigational, retrospective case series involving nebulized administration to the lungs.

Asthma and COPD represent substantial global disease burdens, affecting approximately 260 million (BMJ Open Respiratory Research, Volume 12, Issue 1, 2025) and 400 million (Montes de Oca et al., 2025) individuals worldwide, respectively. Current standard therapies largely focus on symptom management. The Company believes that the reported observations may create an opportunity for nebulized human umbilical cord mesenchymal stem cell‑derived exosomes to provide targeted, potentially disease‑modifying therapy for the lungs.

Dr. Tham Seng Kong, Chief Executive Officer of Alps Group, stated,

“This retrospective case series reports preliminary clinical observations relating to nebulized hUCMSC-derived exosomes in patients with asthma and/or COPD. The reports suggest improvements in pulmonary function, stability in inflammatory markers, and the absence of significant adverse effects. While these findings are promising, larger-scale, controlled studies are necessary to confirm these results and establish standardized treatment protocols.”

As described in the publication, each treatment dose consisted of 1 ml of exosome solution, containing a defined range of exosome particle numbers, mixed with 5 ml of saline. The solution was administered via inhalation using a medical-grade electronic nebulizer for 30 minutes once weekly for 5 weeks.

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or obtain health authority approval.

Details of the study and its findings have been peer-reviewed and published in SAGE Open Medical Case Reports, accessible at: https://journals.sagepub.com/doi/10.1177/2050313X251386547.

About Alps Group

Alps Group Inc is the parent company of Alps Life Sciences Inc., an integrated biotechnology platform integrating research and development, medical services, and wellness solutions of advanced therapies under one unified ecosystem aimed at improving healthcare outcomes globally. Alps Group’s mission is to create a fair healthcare ecosystem, to make advance predictive, preventive, and precision medicine accessible and affordable.

Forward-Looking Statements

Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

Investor Relations Contact
Andrew J. Barwicki
Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alps Group announce about nebulized exosome therapy (ALPS) on January 30, 2026?

They announced potential pipeline expansion after a published retrospective case series reporting nebulized hUCMSC‑derived exosomes in asthma and COPD. According to the company, the study observed pulmonary function improvements, stable inflammatory markers, and no significant adverse effects.

What dosing regimen was used in the published nebulized exosome study referenced by ALPS (ALPS)?

The study used 1 ml exosome solution mixed with 5 ml saline, inhaled via a medical electronic nebulizer for 30 minutes once weekly for five weeks. According to the company, that dosing produced the reported observational outcomes.

Do the published results mean ALPS's nebulized exosome therapy is proven effective and safe?

No; the results are preliminary observations from a retrospective case series, not definitive proof. According to the company, larger randomized, controlled studies are necessary to confirm efficacy and safety and to establish standardized protocols.

How might the published case series affect ALPS's CELESOME(+) exosome program (ALPS)?

The company views the observations as an opportunity to expand exosome-related development beyond CELESOME(+). According to the company, technical experience from CELESOME(+) supports further investigational work but requires additional clinical validation.

Where was the nebulized hUCMSC exosome case series published and registered for the ALPS announcement?

The case series was peer‑reviewed and published in SAGE Open Medical Case Reports and registered with Malaysia’s National Medical Research Register (NMRR ID‑25‑00600‑F4A). According to the company, the paper details the study methodology and findings.